Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (664)	8/10/2004 12:24:51 PM
From: rkrw	Respond to of 1022

Correct, from abgx. Thanks for the pointer. An interesting program. Once/6 month injection. Q2 CC: Additional data were presented by Abgenix's technology licensing partners, including encouraging Phase 1 data for partner Pfizer, XenoMouse technology derived Anti CTLA 4 antibody in melanoma patients and data about AMG162 a XenoMouse derived anti-body that's being developed by Amgen for bone loss. Both of these partner antibodies may result in future milestones and royalties to Abgenix.